Literature DB >> 7304648

Prednisone-induced leukocytosis. Influence of dosage, method and duration of administration on the degree of leukocytosis.

Y Shoenfeld, Y Gurewich, L A Gallant, J Pinkhas.   

Abstract

The long-term pattern of prednisone-induced leukocytosis was examined in 80 patients. Our results disclosed an extremely variable leukocytic responses, in which the white blood cell count surpassed 20,000/mm3 as early as the first day of treatment, an increase that persisted for the duration of therapy. Although the degree of leukocytosis was related to the dosage administered, it did appear sooner with higher doses. Leukocytosis reached maximal values within two weeks in most cases, after which the white blood cell count decreased, albeit not to pretreatment levels. The leukocytosis was attributed predominantly to a rise in the polymorphonuclear white blood cells, a phenomenon that coincided with monocytosis, eosinopenia and a variable degree of lymphopenia. It can be concluded that even small doses of prednisone, administered over a prolonged period of time, can induce extreme and persistent leukocytosis. This observation is of consequence especially when infection is suspected, particularly in an immunocompromised host. However, a shift to the left in the peripheral white blood cells, i.e., more than 6 percent band forms, and the appearance of toxic granulation may assist in the differential diagnosis between infection, in which the latter are observed, and corticosteroid-induced leukocytosis, in which they are rare.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7304648     DOI: 10.1016/0002-9343(81)90363-6

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  35 in total

1.  Evaluation of peripheral blood neutrophil leucocytes in lead-exposed workers.

Authors:  Luigi Di Lorenzo; Andrea Silvestroni; Maria Giuliana Martino; Tommaso Gagliardi; Marisa Corfiati; Leonardo Soleo
Journal:  Int Arch Occup Environ Health       Date:  2006-01-17       Impact factor: 3.015

2.  Modeling interactions between adrenal suppression and T-helper lymphocyte trafficking during multiple dosing of methylprednisolone.

Authors:  F S Chow; A Sharma; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1999-12

3.  Iliopsoas hypertrophy mimicking acute abdomen in a bodybuilder.

Authors:  J Zeiss; R R Smith; A M Taha
Journal:  Gastrointest Radiol       Date:  1987

4.  Correspondence to "Role of neutrophil to lymphocyte and monocyte to lymphocyte ratios in the diagnosis of bacterial infection in patients with fever".

Authors:  Stamatis Karakonstantis; Dimitra Kalemaki
Journal:  Infection       Date:  2017-09-08       Impact factor: 3.553

5.  Pharmacodynamic model for joint exogenous and endogenous corticosteroid suppression of lymphocyte trafficking.

Authors:  M A Milad; E A Ludwig; S Anné; E Middleton; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1994-12

6.  Secondary Antibody Deficiency in Glucocorticoid Therapy Clearly Differs from Primary Antibody Deficiency.

Authors:  Clemens Wirsum; Cornelia Glaser; Sylvia Gutenberger; Baerbel Keller; Susanne Unger; Reinhard E Voll; Werner Vach; Thomas Ness; Klaus Warnatz
Journal:  J Clin Immunol       Date:  2016-03-15       Impact factor: 8.317

7.  Prognostic significance of marked leukocytosis in hospitalized patients.

Authors:  R Chang; G Y Wong
Journal:  J Gen Intern Med       Date:  1991 May-Jun       Impact factor: 5.128

8.  A myelopoiesis gene signature during remission in anti-neutrophil cytoplasm antibody-associated vasculitis does not predict relapses but seems to reflect ongoing prednisolone therapy.

Authors:  T Kurz; M Weiner; C Skoglund; S Basnet; P Eriksson; M Segelmark
Journal:  Clin Exp Immunol       Date:  2014-02       Impact factor: 4.330

9.  Leukocytosis in non hematological malignancies--a possible tumor-associated marker.

Authors:  Y Shoenfeld; A Tal; S Berliner; J Pinkhas
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

10.  Drug-induced hematologic syndromes.

Authors:  David M Mintzer; Shira N Billet; Lauren Chmielewski
Journal:  Adv Hematol       Date:  2009-07-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.